Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Table 2 Current list of FDA-approved PD-L1 inhibitors along with indications, dosages, and bioassay for the PD-L1 expression

PD-L1 inhibitors	Indications	Dosages and schedules	PD-L1 bioassays	PD-L1 cutoff	References
Atezolizumab (MPDL3280A)	NSCLC	1200 mg over 60 min q3 weeks	Roche Ventana SP142	≥ 50% TC or ≥ 10% IC	[42]
	UC			≥ 5% IC	[38]
	ES-SCLC			N/A	[44]
	TNBC	840 mg q1 and 15		≥ 1% IC	[45]
Durvalumab (MEDI4736)	UC	10 mg/kg over 60 min q2 weeks	Roche Ventana SP263	≥ 25% TC or ≥ 25% IC	[59]
Durvalumab (MEDI4736)	Unresectable stage III NSCLC			≥ 1% TC	[60]
Avelumab (MSB0010718C)	MCC	10 mg/kg over 60 min q2 weeks	N/A	N/A	[69]
Avelumab (MSB0010718C)	RCC				[79]

NSCLC non-small cell lung cancer, UC urothelial cancer, MCC Merkel cell carcinoma, TNBC triple-negative breast cancer, RCC renal cell carcinoma, ESSCLC extensive-stage small cell carcinoma, % IC percentage PD-L1 expressing tumor-infiltrating immune cells of any intensity of the tumor area, % TC percentage of PD-L1 expressing tumor cells of any intensity

ISSN: 1756-8722